Evaluation of (S)-10-Hydroxycamptothecin Inhibitor of Herpes Simplex Type 1 Identified from Screening of a Library of Natural Products

Background: Herpes simplex virus type 1 (HSV-1) causes serious illness in humans, especially newborns and immunocompromised hosts. Public health requires the development of new, less toxic anti-HSV-1 drugs. Objectives: This study aimed to evaluate potential anti-herpesvirus activity natural products an extensive library 133 compounds by examining viral titers number plaques. Methods: (S)-10-hydroxycamptothecin (10-HCPT) as inhibitor against DNA replication lowest concentration ranges from a set consisting screening compounds. Each step cycle HSV-1 on A549 cells was evaluated with different assays, including adsorption, penetration, time-of-addition assay, quantitative polymerase chain reaction (PCR). The respective antiviral effects HSV-1AN95 infection were assessed vitro. Results: 10-HCPT found be potent range product library. results showed that significantly affects plaque formation inhibition, half maximal effective (EC50) 0.07 μM. time addition assay suggested had inhibitory effect when added 8 hours after infection. It further confirmed reducing expression late genes glycoprotein (g) protein (VP) (gB, gD, gH, VP1/2, VP16) 4 treatment group compared positive controls real-time PCR. Western blotting are inconsistent other reported results. did not affect gD ICP4 during infection, appeared immediate-early (IE) (L) steps. Conclusions: demonstrated anti-HSV HSV-1. Their dose-dependent specific cellular components might mediate their function rather than cytotoxicity. survey suggests new outlook exploring options for infections.